New information and unexpected uncertainties on optimal antiretroviral therapy during pregnancy course through the new guidelines.
Sponsoring Organization: Department of Health and Human Services (DHHS)Target Audience: Infectious disease specialists, obstetricians, and other clinicians caring for people with HIV
Background and Objective
Approximately 5000 women with HIV give birth each year in the U.S. Comprehensive care, including antiretroviral therapy (ART) during pregnancy, improves maternal outcomes and prevents HIV transmission to the infant. Based on new antiviral safety and pharmacokinetic information, the DHHS has made substantial changes to the perinatal HIV guidelines, last updated in 2017.
Key Points
Reviewing Author
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)
DisclosuresGrant/Research SupportNIH
Editorial BoardsUpToDate; ID Images (idimages.org); Infectious Diseases Society of America COVID-19 Treatment Guidelines; International Antiviral Society–USA (Guidelines Committee)
Leadership Positions in Professional SocietiesHIV Medicine Association; Infectious Diseases Society of America (Board of Directors)